-+ 0.00%
-+ 0.00%
-+ 0.00%

Purple Biotech Completes Non-Human Primates Toxicology Study Of IM1240

Benzinga·01/07/2026 13:05:21
Listen to the news

IM1240 demonstrated improved  safety in a toxicology study at doses up to 300-fold higher than a non-capped comparator

IM1240's pharmacokinetic profile showed increased systemic exposure and a prolonged circulating half-life enabled by its human serum albumin moiety and capping design

IM1240 on track towards first-in-human clinical trials, with regulatory submission planned for the second half of 2026